Liraglutide (Victoza or Sandexa)

1. Quick Facts

2. Summary

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes mellitus and later approved for chronic weight management. It was the first GLP-1 receptor agonist to demonstrate significant cardiovascular benefit in a large randomized outcomes trial.

Research surrounding Liraglutide focuses on glycemic control, appetite regulation, body weight reduction, cardiovascular protection, and improvements in overall metabolic health. Although newer once-weekly incretin therapies have largely replaced it in clinical practice, Liraglutide remains one of the best-studied GLP-1 receptor agonists with an extensive body of human clinical evidence.

What People Commonly Claim

• Reduces appetite and food cravings
• Produces meaningful weight loss
• Improves blood sugar control
• Reduces cardiovascular risk
• Improves long-term metabolic health
• Provides more consistent appetite suppression because of daily administration

What the Literature Actually Shows

• Liraglutide is an extensively studied GLP-1 receptor agonist with robust human clinical evidence.
• Clinical trials consistently demonstrate significant improvements in glycemic control.
• Daily administration produces clinically meaningful reductions in body weight.
• Large cardiovascular outcome trials demonstrate reductions in major adverse cardiovascular events in appropriate patient populations.
• Gastrointestinal adverse effects remain the most frequently reported side effects.
• Although highly effective, average weight loss is generally less than that observed with newer dual- and triple-incretin therapies.

3. Reconstitution Guide

At this concentration:
• 0.6 mg = 0.060 mL (6.0 units)
• 1.2 mg = 0.120 mL (12.0 units)
• 1.8 mg = 0.180 mL (18.0 units)
• 2.4 mg = 0.240 mL (24.0 units)
• 3.0 mg = 0.300 mL (30.0 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

4. Route of Administration

Liraglutide is most commonly administered as a subcutaneous injectable GLP-1 receptor agonist.

5. Common Research Protocols

6. Mechanism of Action

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that closely mimics the activity of endogenous GLP-1, an incretin hormone released by the gastrointestinal tract following nutrient intake.

Activation of GLP-1 receptors stimulates glucose-dependent insulin secretion while suppressing glucagon release during periods of elevated blood glucose. Liraglutide also slows gastric emptying and acts on appetite-regulating centers within the hypothalamus, promoting satiety and reducing caloric intake. These combined actions contribute to improved glycemic control and gradual body weight reduction.

Potential downstream effects discussed in research include:

• Enhanced glucose-dependent insulin secretion
• Reduced glucagon secretion
• Delayed gastric emptying
• Increased satiety
• Reduced caloric intake
• Improved long-term glycemic control
• Potential cardiovascular and renal protective effects

Unlike newer once-weekly GLP-1 receptor agonists, Liraglutide’s approximately 13-hour half-life requires daily administration to maintain consistent receptor activation and therapeutic effects.

7. Potential Benefits

• Improved glycemic control
• Reduction in HbA1c
• Clinically meaningful body weight reduction
• Reduced appetite and caloric intake
• Lower risk of major adverse cardiovascular events in appropriate patient populations
• Potential slowing of diabetic kidney disease progression
• Low intrinsic risk of hypoglycemia when used without insulin or insulin secretagogues
• Extensive long-term human safety data

8. Potential Risks / Side Effects

Moderate

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal discomfort
• Reduced appetite
• Injection-site reactions
• Headache
• Possible dehydration secondary to gastrointestinal side effects
• Rare reports of pancreatitis
• Possible gallbladder complications during prolonged weight loss

9. Half-Life

Liraglutide has an elimination half-life of approximately 13 hours, allowing for sustained biological activity throughout a 24-hour dosing interval while requiring once-daily administration.

Unlike longer-acting GLP-1 receptor agonists such as Dulaglutide and Semaglutide, Liraglutide does not maintain therapeutic concentrations for an entire week. Consequently, daily dosing is necessary to provide continuous GLP-1 receptor stimulation and consistent metabolic effects.

The compound’s prolonged half-life relative to native GLP-1 is achieved through reversible albumin binding and increased resistance to enzymatic degradation, substantially extending its duration of action compared with endogenous GLP-1.

10. Storage Information

• Store the lyophilized peptide according to the manufacturer’s recommendations until reconstitution.
• After reconstitution with bacteriostatic water, refrigerate at 2–8°C (36–46°F).
• Do not freeze after reconstitution.
• Protect from direct light and excessive heat.
• Discard the solution if it becomes cloudy, develops particulate matter, or changes color.
• When prepared using sterile technique and bacteriostatic water, many researchers limit refrigerated use to approximately 28–30 days.

11. Contraindications / Warnings

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Known hypersensitivity to liraglutide or any formulation component.
• Use caution in individuals with a history of pancreatitis.
• Use caution in individuals with severe gastrointestinal disease, including gastroparesis.
• Monitor hydration status if persistent nausea, vomiting, or diarrhea develops.
• Concurrent use with insulin or insulin secretagogues may increase the risk of hypoglycemia.
• Rapid improvements in glycemic control may temporarily worsen diabetic retinopathy in susceptible individuals.

12. Further Study

Tier 1 – Essential Reading

• Liraglutide for Weight Management: A Critical Review of the Evidence
  Obesity Science & Practice
  A comprehensive review of liraglutide pharmacology, obesity trials, weight-loss efficacy, safety profile, and the SCALE clinical development program. This paper serves as an excellent introduction to liraglutide and its role in obesity research.
• Liraglutide and Glycaemic Outcomes in the LEADER Trial
  Analysis of glycemic outcomes from the landmark LEADER cardiovascular outcomes trial demonstrating durable improvements in HbA1c and long-term glucose management with liraglutide therapy.
• Liraglutide 3.0 mg and Intensive Behavioral Therapy (SCALE IBT)
  Randomized controlled trial evaluating liraglutide combined with intensive lifestyle intervention for chronic weight management, illustrating the additive benefits of behavioral therapy and pharmacologic treatment.

Tier 2 – Mechanisms & Specialized Applications

• GLP-1 Receptor Agonists in Type 2 Diabetes: Mechanisms That Underlie Cardiovascular Effects
  An excellent review explaining how GLP-1 receptor agonists influence endothelial function, inflammation, atherosclerosis, myocardial metabolism, and cardiovascular risk reduction beyond glycemic control.
• Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health
  A modern systematic review comparing liraglutide with newer GLP-1 receptor agonists and multi-agonists while summarizing cardiovascular, renal, metabolic, and safety outcomes across the incretin drug class.

Tier 3 – Advanced Cardiovascular Outcomes

• Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events
  JAMA Cardiology
  A post hoc analysis of the LEADER trial demonstrating that liraglutide reduced both first and recurrent major adverse cardiovascular events, providing a broader assessment of cardiovascular benefit than analyses limited to first events alone.

CKF Note: Liraglutide was the first GLP-1 receptor agonist to convincingly demonstrate cardiovascular benefit in a large randomized outcomes trial, helping establish incretin-based therapies as a cornerstone of modern metabolic medicine. Although newer dual- and triple-agonist compounds generally produce greater weight loss, liraglutide remains one of the most extensively studied agents in the class and continues to serve as an important benchmark for GLP-1 research.

13. Research References

1. Liraglutide for Weight Management: A Critical Review of the Evidence. Obesity Science & Practice. PMCID: PMC5358074.
2. Liraglutide and Glycaemic Outcomes in the LEADER Trial. PMCID: PMC6250637.
3. Liraglutide 3.0 mg and Intensive Behavioral Therapy (SCALE IBT). PMCID: PMC7065111.
4. GLP-1 Receptor Agonists in Type 2 Diabetes: Mechanisms That Underlie Cardiovascular Effects. PMCID: PMC6292070.
5. Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health. PMCID: PMC10923257.
6. Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. JAMA Cardiology. PMCID: PMC6865601.

14. Last Reviewed

Last Reviewed: July 2026